Skip to content

What Now, What Next? Appropriate Management for mUC
How I Practice Video #1: Treatment Landscape for mUC
*Pre-Assessment*

Before you view this activity, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. 

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
1.What are your What are your specialty & credentials?(Required.)
2.What is your community of practice?
3.What was the most common ≥ grade 3 TRAE associated with enfortumab-vedotin and pembrolizumab in EV-302/ KEYNOTE-A39?(Required.)
4.In JAVELIN Bladder 100 trial, what was the OS rate at 1 year for patients treated with avelumab maintenance therapy?(Required.)
5.A 72-year-old man with mUC is found to have progressive disease on restaging scans 10 months after receiving 1L gemcitabine and cisplatin. Which of the following is the preferred NCCN 2L treatment for this patient?
6.In THOR, cohort 1, what was the mPFS for patients treated with erdafitinib?
7.Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity). 

Completing the fields below does not immediately qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

*Please note that we will not forward or sell your contact information.
Privacy & Cookie Notice